{"organizations": [], "uuid": "438d862903ed3060f76ac66be50d955550544c91", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-zafgen-reports-strong-clinical-pro/brief-zafgen-reports-strong-clinical-progress-and-updates-outlook-for-2018-idUSASB0BZVH", "country": "US", "domain_rank": 408, "title": "BRIEF-Zafgen Reports Strong Clinical Progress And Updates Outlook For 2018", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-05T14:16:00.000+02:00", "replies_count": 0, "uuid": "438d862903ed3060f76ac66be50d955550544c91"}, "author": "", "url": "https://www.reuters.com/article/brief-zafgen-reports-strong-clinical-pro/brief-zafgen-reports-strong-clinical-progress-and-updates-outlook-for-2018-idUSASB0BZVH", "ord_in_thread": 0, "title": "BRIEF-Zafgen Reports Strong Clinical Progress And Updates Outlook For 2018", "locations": [], "entities": {"persons": [], "locations": [{"name": "silicon valley bank", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "zafgen inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 18 PM / Updated 3 minutes ago BRIEF-Zafgen Reports Strong Clinical Progress And Updates Outlook For 2018 Reuters Staff \nJan 5 (Reuters) - Zafgen Inc: \n* ZAFGEN REPORTS STRONG CLINICAL PROGRESS AND UPDATES OUTLOOK FOR 2018 \n* ZAFGEN- INCREASED CASH POSITION DURING Q4, EXPECTS TO END CALENDAR YEAR 2017 WITH OVER $100 MILLION IN CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES \n* ZAFGEN INC - WELL-CAPITALIZED TO SUPPORT ITS CLINICAL-STAGE DEVELOPMENT PROGRAMS BEYOND FIRST HALF OF 2019 \n* ZAFGEN - ‍ENTERED A $20 MILLION VENTURE DEBT FINANCING AGREEMENT WITH SILICON VALLEY BANK ON DEC 29, EXTENDING EXPECTED CASH RUNWAY BEYOND H1 2019​ \n* ZAFGEN INC - TOPLINE DATA ARE EXPECTED IN MID-YEAR 2018 FOR ZGN-1258 \n* ZAFGEN -FOR ZGN-1258,‍ BEGINNING IND APPLICATION-ENABLING WORK IN Q1 FOR FILING WITH U.S. FDA, BEGINNING PHASE 1 CLINICAL DEVELOPMENT BY END OF YEAR​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-05T14:16:00.000+02:00", "crawled": "2018-01-05T14:32:13.003+02:00", "highlightTitle": ""}